Molecular Pharmaceutics最新文献

筛选
英文 中文
Molecular Insights into the Wet Granulation Mechanisms of Drugs with Different Solubilities 不同溶解度药物湿制粒机制的分子研究
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-19 DOI: 10.1021/acs.molpharmaceut.6c00831
Yu Zhou, Chiyu Huang, Hanwen Zhang, Qi Ren, Zhiyu Chen, Zeng Liu, Huanyu Zhou, Taigang Zhou, Shuangkou Chen, Chuanyun Dai
{"title":"Molecular Insights into the Wet Granulation Mechanisms of Drugs with Different Solubilities","authors":"Yu Zhou,&nbsp;Chiyu Huang,&nbsp;Hanwen Zhang,&nbsp;Qi Ren,&nbsp;Zhiyu Chen,&nbsp;Zeng Liu,&nbsp;Huanyu Zhou,&nbsp;Taigang Zhou,&nbsp;Shuangkou Chen,&nbsp;Chuanyun Dai","doi":"10.1021/acs.molpharmaceut.6c00831","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00831","url":null,"abstract":"<p>Wet granulation is an interfacial reconstruction process mediated by liquid binders. However, the mechanisms underlying the distinct granulation behaviors of drugs with different solubilities remain poorly understood due to a lack of molecular-level insight. Here, we elucidate these mechanisms using density functional theory (DFT) calculations and molecular dynamics (MD) simulations. Three model drugs with distinct solubilities<span></span>aminophylline (AMI), metformin hydrochloride (MET), and diclofenac sodium (SD)<span></span>were selected. The results show that differences in granulation behavior cannot be attributed solely to solubility; rather, they arise from variations in interfacial interactions may be governed by crystal structure. Molecular simulations further reveal that crystal structure contributes to macroscopic granulation outcomes by regulating the dynamics of interfacial water molecules.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5762–5774"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined Importance of Non-Specific and Specific Interactions on the Cellular Uptake Kinetics of Peptide-Functionalized Mesoporous Silica Nanoparticles Targeting Integrins In Vitro 非特异性和特异性相互作用对体外靶向整合素的肽功能化介孔二氧化硅纳米颗粒细胞摄取动力学的综合重要性
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-25 DOI: 10.1021/acs.molpharmaceut.6c00721
Janina Hald, Bianca Leutfeldt, Mika Lindén
{"title":"Combined Importance of Non-Specific and Specific Interactions on the Cellular Uptake Kinetics of Peptide-Functionalized Mesoporous Silica Nanoparticles Targeting Integrins In Vitro","authors":"Janina Hald,&nbsp;Bianca Leutfeldt,&nbsp;Mika Lindén","doi":"10.1021/acs.molpharmaceut.6c00721","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00721","url":null,"abstract":"<p>Determination of optimum ligand densities on nanoparticles that result in the highest nanoparticle uptake by the target cells has been the focus of many recent reports. However, analysis of the parallel influence of other important parameters affecting nanoparticle uptake, for example, charge, has achieved less attention. Here, we report results related to the influence of targeting peptide surface concentration on the cellular uptake of mesoporous silica nanoparticles, MSNs, targeting α<sub>v</sub>β<sub>3</sub> integrins on the cell lines differing in receptor density. For each particle system, the total peptide surface concentration was kept constant, and the targeting peptide concentration was varied through variations of the ratio of the targeting peptide to scrambled peptide. Both anionic carboxylated and cationic aminated MSNs were used. Clear differences in the cellular uptake kinetics as well as the degree of active targeting were observed, which are rationalized through a combination of nanoparticle adhesion strength to the cellular membrane influenced both by the presence of targeting ligand and particle surface charge and of receptor density on the target cells. Our results highlight the important influence of non-specific nanoparticle−cell interactions on active targeting outcomes.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5609–5619"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineering Hybrid Peptides and Ionic Liquid-Peptide Conjugates for a Fast Action on Bacterial Membranes 工程杂化肽和离子液体-肽偶联物在细菌膜上的快速作用
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-24 DOI: 10.1021/acs.molpharmaceut.6c00194
Mariana Ferreira, Ana Gomes, Joana Maciel, Cátia Barroso, Alexandra Plácido, Cláudia Nunes, Salette Reis, Paula Gameiro, Paula Gomes
{"title":"Engineering Hybrid Peptides and Ionic Liquid-Peptide Conjugates for a Fast Action on Bacterial Membranes","authors":"Mariana Ferreira,&nbsp;Ana Gomes,&nbsp;Joana Maciel,&nbsp;Cátia Barroso,&nbsp;Alexandra Plácido,&nbsp;Cláudia Nunes,&nbsp;Salette Reis,&nbsp;Paula Gameiro,&nbsp;Paula Gomes","doi":"10.1021/acs.molpharmaceut.6c00194","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00194","url":null,"abstract":"<p>Fast-acting peptide-based antimicrobials that target bacterial membranes are herein addressed and promise a breakthrough in chronic wound care. Two peptide hybrids (3.1-PP4 and PP4-3.1), engineered by us, resulted from linking PP4 (a non-antimicrobial anti-aging peptide used in cosmetics) to the antimicrobial peptide 3.1. In contrast, the replacement of the latter with an antimicrobial ionic liquid afforded an ionic liquid-peptide conjugate C<sub>16</sub>-Im-PP4. Herein, we demonstrate their rapid bactericidal action by targeting bacterial membranes via a combination of biophysical assays and microscopy using liposome models of bacterial membranes and live bacteria. Interestingly, the peptide hybrids share a similar membrane-disruptive mechanism against Gram-positive <em>Staphylococcus aureus</em> and Gram-negative <em>Escherichia coli</em>. In turn, the ionic liquid-peptide conjugate C<sub>16</sub>-Im-PP4 displayed bacterial-type-dependent behavior. These findings underscore the potential of peptide-based agents to address chronic wounds, which remain vulnerable to infection due to prolonged inflammation and rising antibiotic resistance that is increasingly regarded as a “silent pandemic”.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5272–5287"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Dynamics Simulation-Guided 124I/211At-Labeled Aromatic Amide Derivatives as a Potential Theranostic Pair for Melanoma 分子动力学模拟引导的124I/ 2111at标记芳香酰胺衍生物作为黑色素瘤的潜在治疗对
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-23 DOI: 10.1021/acs.molpharmaceut.6c00835
Huan Ma, Wenbing Ding, Lili Pan, Mingxing Huang, Ning Liu, Jing Su, Feize Li, Wei Zhang
{"title":"Molecular Dynamics Simulation-Guided 124I/211At-Labeled Aromatic Amide Derivatives as a Potential Theranostic Pair for Melanoma","authors":"Huan Ma,&nbsp;Wenbing Ding,&nbsp;Lili Pan,&nbsp;Mingxing Huang,&nbsp;Ning Liu,&nbsp;Jing Su,&nbsp;Feize Li,&nbsp;Wei Zhang","doi":"10.1021/acs.molpharmaceut.6c00835","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00835","url":null,"abstract":"<p>Targeted alpha therapy (TAT) based on <sup>211</sup>At represents a highly promising therapeutic strategy for various cancers, yet the rational design of molecular structures remains challenging in practical translation. In this work, we proposed a molecular dynamics (MD) simulation-guided strategy for constructing <sup>124</sup>I/<sup>211</sup>At-labeled aromatic amide derivatives as a potential theranostic pair for melanoma. The interaction process between melanin and a series of aromatic amide derivatives was first investigated via MD simulation, emphasizing that dimethylamino derivatives possessed superior binding ability. Furthermore, radioiodinated dimethylamino derivative [<sup>124</sup>I]Dm-5-IPLA was proven to have the best tumor-targeting capability and favorable pharmacokinetics via systematic experimental investigations including in vitro cell testing, in vivo PET imaging, and ex vivo biodistribution investigations. Its therapeutic analogue, [<sup>211</sup>At]Dm-5-APLA, accordingly exhibited effective tumor growth inhibition and satisfactory safety in the TAT of B16F10 tumor-bearing mice, indicating the potential of <sup>124</sup>I/<sup>211</sup>At-labeled aromatic amide derivatives for melanoma theranostics.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5775–5786"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structural Response of Amorphous Active Pharmaceutical Ingredients with Flexible Molecules to High Pressure 具有柔性分子的非定形活性药物成分对高压的结构响应
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-05 DOI: 10.1021/acs.molpharmaceut.6c00829
Anna Janowska, Gaston Garbarino, Joao Elias F. S. Rodrigues, Samuel Gallego Parra, Karolina Jurkiewicz
{"title":"Structural Response of Amorphous Active Pharmaceutical Ingredients with Flexible Molecules to High Pressure","authors":"Anna Janowska,&nbsp;Gaston Garbarino,&nbsp;Joao Elias F. S. Rodrigues,&nbsp;Samuel Gallego Parra,&nbsp;Karolina Jurkiewicz","doi":"10.1021/acs.molpharmaceut.6c00829","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00829","url":null,"abstract":"<p>The objective of this study was to examine the intra- and intermolecular structure of two active pharmaceutical ingredients characterized by van der Waals flexible molecules<span></span>probucol and loratadine<span></span>in their liquid and glassy states under ambient and high-pressure conditions. We investigated how compression influences local packing motifs in these systems and whether the structural features observed in supercooled liquids under ambient and high-pressure conditions resemble those found in ordinary and pressure-densified glasses. Structural evolution was characterized using ambient- and high-pressure X-ray diffraction supported by molecular dynamics simulations. Total and partial structure factors, pair distribution functions, and local structural parameters were calculated from molecular dynamics models that were consistent with experimental diffraction data. The results show that compression primarily modifies local molecular packing and the distribution of various intermolecular contacts while inducing only minimal changes in the conformations of these flexible molecules. Regarding the intermolecular structure, compression affects the medium-range order, increases local structural heterogeneity, and enhances the population of short O−H···S and Cl···Cl contacts. These features are less pronounced in the corresponding liquid and glass states at ambient pressure, within the pressure and temperature ranges studied here, as well as in crystal structures. Upon decompression, these structural characteristics may either relax or exhibit partial similarity to those observed in supercooled pressurized liquids. While analogous phenomena have been discussed for glasses with highly interconnected networks (such as silica-based glasses), our results indicate that similar effects can also appear in molecular pharmaceutical systems. Our results provide molecular-level insight into pressure-induced structural organization in pharmaceutical liquids and motivate further studies on how such structural changes may relate to the properties of the resulting glassy states.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5750–5761"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Image-Based Quantification of Amorphous Solid Dispersion Tablet Formulation Disintegration Profiles in a Custom USP-2 Apparatus 在定制的USP-2仪器中基于图像的非晶固体分散片制剂崩解谱定量
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-16 DOI: 10.1021/acs.molpharmaceut.6c01029
Niloufar Salehi, Pradnya Bapat, Aishwarya Kunigal, Nam Lam, Youlin Liu, Zhanjie Liu, David Sperry
{"title":"Image-Based Quantification of Amorphous Solid Dispersion Tablet Formulation Disintegration Profiles in a Custom USP-2 Apparatus","authors":"Niloufar Salehi,&nbsp;Pradnya Bapat,&nbsp;Aishwarya Kunigal,&nbsp;Nam Lam,&nbsp;Youlin Liu,&nbsp;Zhanjie Liu,&nbsp;David Sperry","doi":"10.1021/acs.molpharmaceut.6c01029","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c01029","url":null,"abstract":"<p>Amorphous solid dispersions (ASDs) are single-phase molecular mixtures of amorphous drug and polymer designed to enhance solubility, inhibit crystallization, and improve release rate, increasing bioavailability. During dissolution, water lowers the glass-transition temperature, triggering gelation and polymer chain mobility. This slows erosion compared to that in neat drug systems. Since the tablet surface area controls drug release onset and rate, its quantitative assessment is vital for predicting dissolution and optimizing ASD performance. Traditional methods like United States Pharmacopeia disintegration testing often rely on visual endpoints and may lack sensitivity to formulation nuances. This tool is often being used in the early stages of formulation development, and it is not an efficient testing method for eroding drug product erosion testing. Imaging techniques, such as magnetic resonance imaging and X-ray microtomography (μCT), are resource-intensive, while mass loss tracking is laborious, inefficient, and prone to reproducibility issues. This project introduces a novel image-based disintegration method using a custom USP-2 apparatus with camera monitoring, directly correlating disintegration/erosion mechanisms with dissolution performance. The study includes apparatus design, formulation development, and image analysis. The erosion and dissolution profile of Ritonavir-PVPVA-based ASD (20% drug loading) formulations with different levels of disintegrants, compressed under two different compression forces, were studied with the USP-2 custom-designed device. Erosion was quantified via time-lapse imaging algorithms that segmented tablet boundaries to calculate the longitudinal and transverse surface area profiles. Findings confirm the method’s viability for erosion profiling as a robust method for quantifying release mechanisms. Compression force across the range (8−10 kN) revealed negligible influence on erosion, as shown by consistent profiles. The formulation that contained high microcrystalline cellulose (MCC) and no lactose showed swelling, followed by erosion in its release mechanism, while a formulation with low MCC and high lactose exhibited a purely erosion-based release mechanism. This method improves formulation predictability and provides insights for ASD drug product release mechanisms.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5905–5913"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI-Assisted Analysis of Clinical Trials to Identify Failed Drugs for Revival via Drug Delivery Technologies 人工智能辅助临床试验分析,通过给药技术识别失败的药物
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-04 DOI: 10.1021/acs.molpharmaceut.6c00594
Nianwu Wang, Rui Zhang, Hong-Bo Pang
{"title":"AI-Assisted Analysis of Clinical Trials to Identify Failed Drugs for Revival via Drug Delivery Technologies","authors":"Nianwu Wang,&nbsp;Rui Zhang,&nbsp;Hong-Bo Pang","doi":"10.1021/acs.molpharmaceut.6c00594","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00594","url":null,"abstract":"<p>Numerous drug candidates showed great promise in experimental and preclinical investigations but failed in clinical trials. One cause to this problem may be nonspecific drug biodistribution, leading to adverse effects in healthy organs. Drug delivery technologies are developed to overcome this exact problem by navigating drugs more selectively to the disease sites. Therefore, they hold the promise to revive at least some failed drugs. However, it is challenging to identify such candidates revivable by drug delivery: first, there lacks systemic survey and documentation of drug biodistribution in patients during the trials; second, clinical trial results, especially the failed ones, are often reported in unstructured and/or inconsistent language. Here, we harnessed the recent advances in artificial intelligence (AI) agents and large language models (LLMs) to tackle with the second problem. An OpenAI-based framework was developed to systemically analyze terminated trials on ClinicalTrials.gov. This framework integrated structured extraction of clinical trial information, disease-site inference with evaluation based on predefined screening criteria, which is unwanted biodistribution (UB failure) reflected by the difference in the anatomical locations between adverse effects and targeted diseases. We also paired this with the analysis of drug types and physicochemical properties (e.g. molecular weight and hydrophobicity). Using a validation set, the model achieved accuracies of 89.69% for UB failure classification, 91.75% for small molecule drug classification, and 88.66% for hydrophobicity classification. We then applied this analysis to all terminated ClinicalTrials.gov trials, which identified 817 trials possibly failed due to UB, and top ten small molecule drugs likely suitable for our peptide-guided delivery platform. Overall, this study may provide a new direction to apply AI technologies for drug development, and inspire future investigations of clinical reports and public information from the perspective of delivery technology applications.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5476–5488"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Voices in Molecular Pharmaceutics: Meet Dr. Ritika Gupta Who Seeks to Light up Pediatric Tumors with Targeted Fluorescence Imaging Agents 分子药剂学的声音:会见Ritika Gupta博士,他寻求用靶向荧光显像剂照亮儿科肿瘤
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-28 DOI: 10.1021/acs.molpharmaceut.6c01111
Ritika Gupta
{"title":"Voices in Molecular Pharmaceutics: Meet Dr. Ritika Gupta Who Seeks to Light up Pediatric Tumors with Targeted Fluorescence Imaging Agents","authors":"Ritika Gupta","doi":"10.1021/acs.molpharmaceut.6c01111","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c01111","url":null,"abstract":"","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5161–5162"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GenMAS: A Machine Learning-Based Modeling and Assessment Strategy for ADMET Profiling and its Application in PBPK Simulation GenMAS:基于机器学习的ADMET分析建模与评估策略及其在PBPK仿真中的应用
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-10-12 DOI: 10.1021/acs.molpharmaceut.6c00563
Yaxin Gu, Peng Qi, Lingling Ma, Guodong Zhang, Biao Lu, Fanglong Yang, Haizhou Zhang, Xiaozhen Wang, Hongcan Ren
{"title":"GenMAS: A Machine Learning-Based Modeling and Assessment Strategy for ADMET Profiling and its Application in PBPK Simulation","authors":"Yaxin Gu,&nbsp;Peng Qi,&nbsp;Lingling Ma,&nbsp;Guodong Zhang,&nbsp;Biao Lu,&nbsp;Fanglong Yang,&nbsp;Haizhou Zhang,&nbsp;Xiaozhen Wang,&nbsp;Hongcan Ren","doi":"10.1021/acs.molpharmaceut.6c00563","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00563","url":null,"abstract":"<p>Evaluation of pharmacokinetic (PK) properties is crucial for the discovery of high-quality drug candidates while minimizing unnecessary biological and clinical trial costs. Compared with in vitro and in vivo studies, in silico methods offer a faster and more cost-efficient alternative. However, despite advances in computational approaches, accurate PK assessment and simulation remain challenging. Current industrial applications are often hindered by a heavy reliance on animal data, limited flexibility, and insufficient project-specific customization. In this study, we present GenMAS, a machine learning (ML)-based strategy designed for comprehensive modeling and evaluation of PK properties. GenMAS was evaluated for its performance in ADMET property prediction and its applicability to physiologically based pharmacokinetic (PBPK) simulation. This strategy synergistically integrated three functional modules: (1) ADMET property prediction module, (2) ML-informed PBPK modeling module, and (3) self-developed high-throughput ADMET-PBPK screening module. The ADMET prediction module was assessed using 10-fold cross-validation, internal test sets, and external validation sets. Cross-validation demonstrated robust performance, with the models yielding an average AUC (area under the curve) of 0.879 and an accuracy of 0.828. For independent test sets, classification accuracy ranged from 70.2% to 88.7%, while average R<sup>2</sup> for physicochemical properties exceeded 0.76. The predictive robustness of GenMAS was further confirmed using in-house project datasets, demonstrating its utility in real-world drug discovery. Furthermore, we developed a ML-informed PBPK module and a high-throughput ADMET-PBPK screening module. In the ML-informed module, ML-predicted compound-specific parameters were integrated into a GastroPlus® rat PBPK model. For 9 intravenously administered compounds, the predicted systemic exposures fell within a two-fold error range of observed data, with a 66.7% accuracy for elimination half-life. The high-throughput module couples ADMET predictions with a minimal PBPK model to enable customizable PK screening. Notably, GenMAS can complete ADMET predictions and PK simulations for 100 compounds in approximately 12 s. GenMAS offers a scalable, structure-based workflow to support early-stage drug discovery.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5436–5449"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149305658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Galactosylated Camptothecin (Gal-CPT) as a New Anticancer Prodrug Sequentially Activated by Dual Tumor-Specific Enzymes 半乳糖基化喜树碱(Gal-CPT)作为一种新的抗癌前药被双肿瘤特异性酶顺序激活
IF 4.9 2区 医学
Molecular Pharmaceutics Pub Date : 2026-11-02 Epub Date: 2026-09-26 DOI: 10.1021/acs.molpharmaceut.6c00687
Chuangchuang Fan, Zirui Jiao, Yonghui Shi, WenMing Chen, Wen Chong Ye, Xiaoyang Wang, Chunmei Wang, Keyu Zhang, Zhonghui Ma, Li Lv, Wen Zhou
{"title":"Galactosylated Camptothecin (Gal-CPT) as a New Anticancer Prodrug Sequentially Activated by Dual Tumor-Specific Enzymes","authors":"Chuangchuang Fan,&nbsp;Zirui Jiao,&nbsp;Yonghui Shi,&nbsp;WenMing Chen,&nbsp;Wen Chong Ye,&nbsp;Xiaoyang Wang,&nbsp;Chunmei Wang,&nbsp;Keyu Zhang,&nbsp;Zhonghui Ma,&nbsp;Li Lv,&nbsp;Wen Zhou","doi":"10.1021/acs.molpharmaceut.6c00687","DOIUrl":"https://doi.org/10.1021/acs.molpharmaceut.6c00687","url":null,"abstract":"<p>Camptothecin (CPT) and its clinically used derivatives are still plagued by severe off-target toxicities. In this study, we designed a galactosylated CPT (Gal-CPT) prodrug incorporating an enzymatically cleavable diethylene glycol linker. <em>In vivo</em> experimental results verified that Gal-CPT exhibited markedly better antitumor efficacy (59.98 ± 4.75% vs 20.52 ± 3.10%) and stronger tumor-specific accumulation than free CPT. This prodrug maintained excellent stability against hydrolysis and remained stable in acidic/neutral solutions, liver microsomes, plasma, and CYP450 metabolic systems. Notably, it could achieve the targeted release of active CPT through sequential cleavage of glycosidic and ester bonds. This activation process was triggered by tumor-enriched CYP1B1 and CYP3A5 at both the enzymatic and cellular levels. Molecular docking and molecular dynamics (MD) simulations further validated this activation mechanism. Additionally, Gal-CPT possessed favorable water solubility and prominent tumor-targeting capability, accompanied by a prolonged half-life (<em>T</em><sub>1/2</sub> = 2.6 h vs 0.75 h). Overall, this dual-enzyme-responsive prodrug offers a promising strategy for precise chemotherapy.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 11","pages":"5572–5584"},"PeriodicalIF":4.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149306046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书